Discovering SRGAP2C: A Potential Drug Target for Various Diseases

Target Name: SRGAP2C

NCBI ID: G653464

SRGAP2C

Discovering SRGAP2C: A Potential Drug Target for Various Diseases

SRGAP2C, also known as SLIT-ROBO Rho GTPase activating protein 2 pseudogene 1, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the Rho GTPase family, which is a subclass of GTPases that play a crucial role in regulating cellular signaling pathways. Activating protein 2 (SRGAP2C) is a pseudogene that has not been fully characterized, but is thought to function as a negative regulator of RhoA, a GTPase that is involved in many cellular processes, including cell signaling, cytoskeletal organization, and cell division.

The discovery of SRGAP2C as a potential drug target or biomarker has significant implications for the development of new treatments for various diseases. While more research is needed to fully understand the functions of SRGAP2C and its potential role in disease, its potential as a drug target is being actively explored.

One of the key features of SRGAP2C is its ability to regulate the activity of RhoA. RhoA is a GTPase that is involved in the regulation of many cellular processes, including the formation of signaling pathways, the regulation of cytoskeletal organization, and the control of cell division. It is activated by various factors, including guanosine, which leads to its GTPase activity.

SRGAP2C is thought to function as a negative regulator of RhoA, by preventing its activity. This is done through a process called negative regulation, which involves the formation of a complex between the protein and RhoA. In this complex, SRGAP2C can interact with RhoA and prevent it from activating, thereby inhibiting its GTPase activity.

While the exact mechanism by which SRGAP2C interacts with RhoA is not well understood, studies have shown that it has a critical role in the regulation of cellular processes, including cell signaling, cytoskeletal organization, and cell division. For example, studies have shown that SRGAP2C is involved in the regulation of the formation of stress granules, which are structures that are involved in the delivery of damaged DNA to the cell's endoplasmic system for degradation.

In addition to its role in the regulation of RhoA, SRGAP2C is also thought to be involved in the regulation of other cellular processes. For example, it is involved in the regulation of the production of actin, a protein that is involved in cell signaling and cytoskeletal organization. It is also involved in the regulation of the production of microtubules, which are structures that are involved in cell division.

The potential implications of SRGAP2C as a drug target or biomarker are significant. If its role in the regulation of RhoA and other cellular processes is confirmed, it could be a promising target for new treatments for various diseases. For example, diseases that are characterized by the misregulation of RhoA, such as cancer, neurodegenerative diseases, and developmental disorders, could benefit from new treatments that target SRGAP2C.

While more research is needed to fully understand the functions of SRGAP2C and its potential role in disease, its potential as a drug target is being actively explored. Researchers are using various techniques, including cell-based assays, biochemical assays, and animal models, to study its behavior and determine its potential as a drug target.

In conclusion, SRGAP2C is a protein that is expressed in various tissues and cells throughout the body and is thought to function as a negative regulator of RhoA, a GTPase that is involved in many cellular processes. Its potential as a drug target or biomarker is being actively explored, with research focusing on its role in the regulation of RhoA and other cellular processes. Further studies are needed to fully understand its functions and potential as a drug target.

Protein Name: SLIT-ROBO Rho GTPase Activating Protein 2C

Functions: Human-specific protein that acts as a key modifier of cortical connectivity in the human brain (PubMed:22559944, PubMed:27373832, PubMed:34707291). Acts by inhibiting the functions of ancestral paralog SRGAP2/SRGAP2A, a postsynaptic protein that regulates excitatory and inhibitory synapse maturation and density in cortical pyramidal neurons (PubMed:22559944, PubMed:27373832). SRGAP2C is unstable but is able to heterodimerize with SRGAP2/SRGAP2A, thereby reducing SRGAP2/SRGAP2A levels through proteasome-dependent degradation (PubMed:27373832, PubMed:28333212, PubMed:31822692). Inhibition of SRGAP2/SRGAP2A by SRGAP2C leads to an increase in synaptic density and protracted synaptic maturation of both excitatory and inhibitory synapses (PubMed:27373832, PubMed:34707291). Modifies cortical circuit connectivity by increasing the number of local and long-range cortical inputs received by layer 2/3 pyramidal neurons (PubMed:34707291). Also able to increase the probability of sensory-evoked responses by layer 2/3 pyramidal neurons (PubMed:34707291)

The "SRGAP2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRGAP2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets